Serum chromogranin A level continuously rises with the progression of type 1 diabetes, and indicates the presence of both enterochromaffin-like cell hyperplasia and autoimmune gastritis

Zoltan Herold1*, Magdolna Herold1, Peter Nagy2, Attila Patocs3, Marton Doleschall5, Aniko Somogyi1
12nd Department of Internal Medicine, Semmelweis University, Budapest, Hungary, 11th Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary, 3Department of Laboratory Medicine, Semmelweis University, Budapest, Hungary, 4Hereditary Tumors Research Group, Eotvos Lorand Research Network and Semmelweis University, Budapest, Hungary, and 5Molecular Medicine Research Group, Eotvos Lorand Research Network and Semmelweis University, Budapest, Hungary

Keywords
Autoimmune gastritis, Chromogranin A, Enterochromaffin-like cell hyperplasia

*Correspondence
Zoltan Herold
Tel.: +36-1-266-0926
Fax: +36-1-261-4166
E-mail address: herold.zoltan@med.semmelweis-univ.hu

J Diabetes Investig 2020; 11: 865–873
doi: 10.1111/jdi.13203

INTRODUCTION
Gastric neuroendocrine tumors (NET; or gastric carcinoid) are very rare (1:200,000) in the general population1, but in patients with type 1 diabetes, approximately 100-fold more cases are registered2-4. Gastric NETs might develop from the hyperplastic proliferation of enterochromaffin-like (ECL) cells5,6 or from autoimmune gastritis (AIG)7,8. AIG is present in 5-10% of type 1 diabetes patients9,10 compared with approximately 2% of the non-type 1 diabetes population11, and gastric NETs develop in approximately 4-9% of type 1 diabetes patients with AIG7. Furthermore, ECL hyperplasia, AIG and gastric NETs are observed more often in women compared with men5,8,11,12.

Chromogranin A (CgA) is an acidic and hydrophilic family member of the granin glycoproteins, and primarily produced by neurons, endocrine and neuroendocrine cells, such as the

ABSTRACT
Aims/Introduction: The relationship of chromogranin A (CgA) levels above the normal range with various outcomes, such as glycated hemoglobin levels, enterochromaffin-like cell hyperplasia and autoimmune gastritis, was investigated in type 1 diabetes patients with special regard to the progression of comorbidities.

Materials and Methods: A cohort study on 153 type 1 diabetes patients was carried out with a prospective branch on clinical and laboratory data, and a retrospective branch on histological data obtained by gastroscopy.

Results: Patients with CgA levels above the upper limit of the normal range (n = 28) had significantly higher glycated hemoglobin levels (P = 0.0160) than those with CgA in the normal range (n = 125). The correlation between CgA and glycated hemoglobin was significant (P < 0.0001), but weak (R = +0.32). A slight, but steady elevation (P = 0.0410) in CgA level was observed to co-vary with the duration of type 1 diabetes. Enterochromaffin-like cell hyperplasia and autoimmune gastritis was significantly more frequent (P = 0.0087 for both) in the high CgA group. Detailed analyses on gastric tissue samples confirmed a progression of enterochromaffin-like cell hyperplasia (P = 0.0192) accompanied by CgA elevation (P = 0.0316).

Conclusions: The early detection and follow up of the later progression of enterochromaffin-like cell hyperplasia and autoimmune gastritis into gastric neuroendocrine tumors, which have ~100-fold greater incidence in type 1 diabetes patients, can be achieved by assessment of CgA levels. Therefore, the use of CgA could be considered as a novel auxiliary biomarker in the care of these type 1 diabetes complications.
intrinsic neurons of the enteric nervous system, the chromaffin cells of the adrenal medulla and the ECL cells of the stomach. It is synthesized from 439 amino acids (molecular weight 48kDa) in humans. CgA takes part in the peptide and protein sorting in the Golgi apparatus through its high-capacity and low-affinity calcium-binding function. Furthermore, various biologically active peptides are generated from CgA by the cleavage of different endoproteases during and after secretion. Several of these cleavage products have been found in human tissues: pancreastatin, WE-14, catestatin, cateslytin, vasostatin-I and -II. Serum CgA is one of the most prominently used markers to confirm the diagnosis, and to monitor the effectiveness of the treatment in patients with various neuroendocrine tumors. Blood CgA level might be altered in some other medical conditions, although these do not lessen its impact as a marker generally.

Recent human and animal model studies have suggested that both the CgA protein by itself and some of its cleavage products, most importantly pancreastatin and WE-14, regulate carbohydrate metabolism and contribute to diabetes. Pancreastatin suppresses insulin signaling and inhibits insulin release, and it has an elevated serum level in type 2 and gestational diabetes patients. WE-14 functions as an autoantigen for the diabetogenic, pancreatic-cell-destroying CD4+ T-cell populations in both non-obese diabetic mice and patients with type 1 diabetes. Some relationships between serum CgA level and type 1 diabetes are also described. High CgA levels and an increased frequency of ECL hyperplasia (n = 7) have been reported in type 1 diabetes patients with AIG and partial cell antibody (PCA) positivity (n = 17); however, CgA has not been assessed independently from the PCA status, or correlated with ECL progression. Nevertheless, CgA has been identified as the only independent risk factor for ECL hyperplasia when PCA and gastrin were tested in type 1 diabetes patients.

An observational cohort study was carried out in type 1 diabetes patients to search for relationships between serum CgA levels above the normal range and the various laboratory and clinical outcomes, such as AIG and ECL hyperplasia. Clinical and laboratory measurement data of type 1 diabetes patients were collected in a prospective manner, whereas tissue samples of the stomach were examined for AIG and ECL hyperplasia in a retrospective way. In addition to the latter, frozen samples from a tissue bank were also investigated to search for evidence for AIG and ECL hyperplasia progression.

METHODS
Patients and study design
A total of 153 Hungarian, c-peptide confirmed, islet-cell- and/or glutamic acid decarboxylase antibody-positive type 1 diabetes patients with European ancestry, who attended the Metabolic Clinic of the 2nd Department of Internal Medicine, Semmelweis University, Budapest, Hungary, from 2010 to 2018, were enrolled for the study. Written informed consent was collected from all study participants. Exclusion criteria included the use of acid reducer medications, any kidney diseases, known tumors, ulcerative colitis, Crohn’s disease, systemic rheumatoid arthritis or any conditions changing the serum concentrations of CgA. Patients with autoimmune diseases associated with type 1 diabetes, including autoimmune thyroid disease, celiac disease, pernicious anemia, alopecia areata, vitiligo, Addison’s disease and Sjögren’s syndrome were not excluded. Glycemic control of patients was determined as described in the 2019 guidelines of the American Diabetes Association.

An observational cohort study was carried out, where cohorts were defined by the serum CgA level. On average, the patients (n = 153) had been suffering from diabetes at the time of baseline measurements for 13.47 ± 9.77 years. Follow-up measurements (n = 94) were carried out 18.88 ± 9.80 years from the time of diagnosis. A subpopulation of patients (n = 34) who agreed to undergo gastroscopy all had the disease at the time of the procedure for nearly the same duration as the follow-up patients (20.53 ± 7.60 years).

Clinical data and measurements
Anamnestic, bodyweight and height data were collected, and blood samples were drawn after an 8-h fasting period. Complete blood count, glycated hemoglobin (HbA1c), total-, high- and low-density lipoprotein cholesterol, triglycerides, creatinine, high-sensitivity C-reactive protein, and thyroid-stimulating hormone were measured at the Central Laboratory of Semmelweis University. The estimated glomerular filtration rate was calculated using the Chronic Kidney Disease-Epidemiology Collaboration equations.

Serum CgA levels were measured at the Central Endocrine and Genetic Laboratory of Semmelweis University using the CGA-RIACT radioimmunoassay kit (CISbio International, Gif-sur-Yvette, France) on a RIA-mat 280 (Laborexpert Kft., Diosd, Hungary) automated analyzer. The normal range of serum CgA (19.4–98.1 ng/mL) was obtained from the 95% confidence interval (CI) of 162 healthy individuals, which has been confirmed in previous publications.

Gastroscopy and chromogranin A-specific immunohistochemical staining
Gastroscopy was carried out at the Gastroenterology Clinic of the 2nd Department of Internal Medicine, Semmelweis University. A total of 19 patients with serum CgA levels above the normal range, and 15 patients with normal CgA levels, whose indications were not related to type 1 diabetes, underwent the procedure. Biopsy samples for routine histological examinations and CgA-specific immunohistochemical staining were collected from the fundus, oral and aboral parts of the antrum, and pylorus.

Biopsy samples were processed at the 1st Department of Pathology and Experimental Cancer Research, Semmelweis University. Routine histopathological procedures included
hematoxylin–eosin staining. The presence of Helicobacter pylori was investigated by modified Giemsa staining. The updated Sydney system was used to evaluate activity, atrophy and inflammation. CgA-specific immunohistochemical staining was carried out with the Clone DAK-A3 Monoclonal Mouse Anti-Human Chromogranin A immunohistochemistry kit (M0869, dilution 1:1000; Dako Denmark A/S, Glostrup, Denmark). Immune reactions were carried out in formalin-fixed, paraffin-embedded tissue with 3,3′-diaminobenzidine as chromogen with the Leica Biosystems Bond Polymer Refine Detection kit on a Leica Bond automated immunostainer (Leica Biosystems Newcastle Ltd., Newcastle Upon Tyne, UK). Endogenous neuroendocrine cells of the gastric mucosa served as positive controls.

Histopathological classification of the CgA-positive, ECL cell growths were identified based on descriptions by Solcia et al. Briefly, cells are located randomly and individually in the case of diffuse ECL hyperplasia, cell clusters form a chain of five or more cells in linear ECL hyperplasia, while cells are orderly arranged, forming knots between 100 and 150 μm in size in micronodular ECL hyperplasia.

Statistical analysis
Statistical analyses were carried out within the R for Windows version 3.5.0 environment (R Foundation for Statistical Computing, Vienna, Austria). Two sample t-tests and permutation-based paired t-tests were used for comparisons between groups and paired data, respectively. Fisher’s exact test was used to compare count data. Pearson’s correlation, and linear and logistic regression models were used for testing the in-between effects of various factors. Receiver operating characteristic analysis was carried out to test the sensitivity and specificity of CgA. P < 0.05 was considered as statistically significant; P-values were corrected with the false discovery rate method for the multiple comparisons problem.

A random intercept linear mixed effects model was used to determine the changes in CgA with the progression of type 1 diabetes. R package nlme was used to run the model. The dependent variable in the final model was the natural logarithmic value of serum CgA level, the fixed effect was the duration of type 1 diabetes and patient IDs were used as the random effect.

Ethics approval
This study was carried out in concordance with the World Medical Association Declaration of Helsinki, and approved by the Regional and Institutional Committee of Science and Research Ethics of Semmelweis University. Handling of patient data was in accordance with the General Data Protection Regulation issued by the European Union.

RESULTS
Baseline measurements
A CgA level above the upper limit of the normal range (>98.1 ng/mL) was observed in 18.30% of patients with type 1 diabetes. Patients were divided into two cohorts based on their baseline serum CgA levels. Study participants having levels within the normal range (19.4–98.1 ng/mL) were assigned to the Normal CgA group (n = 125), whereas patients with levels higher than the normal range were assigned to the High CgA group (n = 28).

To test whether other factors, such as age, sex, body mass index and/or the duration of type 1 diabetes, affects the cohorts outlined above, univariate and multivariate logistic regression models were used. None of these factors showed any effect or connection to the grouping variable. Study participants consisted of homogeneous ethnicity (only Hungarians with European ancestry); therefore, no analysis was carried out on the effects of ethnicity. No difference was found in the overall statistical analysis stratified by latent autoimmune diabetes of adults. Therefore, latent autoimmune diabetes of adults and conventional type 1 diabetes patients will not be subgrouped hereinafter.

HbA1C levels in the High CgA group were significantly higher compared with those in the Normal CgA group (P = 0.160; Table 1). A significant positive correlation was found between CgA and HbA1C (Pearson’s R = +0.32, P < 0.0001). However, as determined by a regression model, the increase in HbA1C only slightly explained the increase in CgA (adjusted R² = 0.0992, P < 0.0001). Based on the HbA1C values, 69.6% of the patients had poor glycemnic control (HbA1C ≥7.0%, which equals to ≥53 mmol/mol) in the Normal CgA group, whereas this figure rose to 96.4% of patients in the High CgA group (P = 0.0326). The occurrence of type 1 diabetes-specific antibodies, latent autoimmune diabetes of adults and the commonly associated comorbidities of type 1 diabetes, such as hypertension, thyroid diseases (both autoimmune and non-autoimmune forms), celiac disease, alopecia areata, pernicious anemia, vitiligo, Addison’s disease and Sjögren’s syndrome, did not differ between the two groups (Table 1).

Changes in serum chromogranin A levels with the duration of type 1 diabetes
To determine whether the CgA level changes with respect to the duration of type 1 diabetes, we chose two prospective approaches. First, the patients were recalled for a follow-up measurement of CgA. We were able to reach 94 patients from the original 153 (call-back rate 61.4%). The mean duration between the baseline and follow-up measurements was 4.73 ± 2.27 years. The elevation of serum CgA levels in the Normal CgA group was significant (n = 77, P = 0.0277), whereas no significant change was observed in the High CgA group (n = 17, P = 0.2202), or in both groups combined (P = 0.0571; Table 2). The CgA levels of five (6.5%) Normal CgA group patients were above the normal range at the follow-up measurement.

Second, a random intercept linear mixed effect model was constructed, where not only the paired, but all the baseline and
further repeated measurements from all of the 153 study participants were used. A total of 364 CgA measurements were collected. Based on the estimations given by the statistical model, a significant 0.40–1.82% average increase in the serum CgA concentrations can be expected annually ($P = 0.0410$).

### Gastroscopy results

Gastroscopy was carried out in 15 patients of the Normal CgA group, and 19 patients of the High CgA group. Frequencies of gastroesophageal reflux disease, *Helicobacter pylori* positivity and/or chronic gastritis were statistically not different between

---

**Table 1** | Anamnestic and laboratory measurement data

|                                | Normal CgA ($n = 125$) | High CgA ($n = 28$) | $P$-value |
|--------------------------------|-------------------------|---------------------|-----------|
| **Age (years)**                | 35.37 ± 12.27           | 36.46 ± 9.88        | 0.7486    |
| **Duration of diabetes (years)** | 12.89 ± 10.01           | 16.07 ± 8.29        | 0.2432    |
| **C-peptide (ng/mL)**          | 0.41 ± 0.76             | 0.33 ± 1.20         | 0.8554    |
| **Islet cell antibody positivity** | 62                      | 10                  | 1.0000    |
| **Glutamic acid decarboxylase antibody positivity** | 71                      | 11                  | 1.0000    |
| **Chromogranin A (ng/mL)**     | 49.80 ± 19.58           | 291.73 ± 248.32     | 0.0006    |
| **HbA1C (%)**                  | 8.29 ± 1.96             | 9.62 ± 2.02         | 0.0160    |
| **HbA1C (mmol/mol)**           | 67 ± 21.4               | 82 ± 22.1           | 0.0160    |
| **Glycemic control of patients** |                          |                     |           |
| Well controlled diabetes       | 38 (30.4%)              | 1 (3.6 %)           | 0.0326    |
| Poorly controlled diabetes     | 87 (69.6%)              | 27 (94.4 %)         | 0.3828    |
| **White blood cell count (G/L)** | 7.41 ± 2.16             | 7.94 ± 2.03         | 0.3828    |
| **Red blood cell count (T/L)** | 4.97 ± 0.51             | 4.64 ± 0.55         | 0.0356    |
| **Hemoglobin (g/L)**           | 144.70 ± 15.04          | 131.71 ± 19.37      | 0.0160    |
| **Hematocrit (L/L)**           | 0.429 ± 0.043           | 0.398 ± 0.045       | 0.0160    |
| **Mean corpuscular volume (fL)** | 86.30 ± 3.34            | 85.44 ± 6.76        | 0.7075    |
| **Mean corpuscular hemoglobin (pg)** | 291.73 ± 248.32        | 332.19 ± 16.75      | 0.2978    |
| **Mean corpuscular hemoglobin concentration (g/L)** | 13.01 ± 0.80           | 13.81 ± 1.60        | 0.0620    |
| **Platelets (G/L)**            | 273.74 ± 65.88          | 309.59 ± 69.25      | 0.0682    |
| **Creatinine (µmol/L)**        | 72.71 ± 13.06           | 79.14 ± 26.35       | 0.3828    |
| **Estimated glomerular filtration rate (mL/min/1.73 m²)** | 103.94 ± 16.98          | 97.99 ± 25.07       | 0.3828    |
| **Total cholesterol (mmol/L)** | 5.06 ± 0.97             | 5.68 ± 1.70         | 0.2432    |
| **High-density lipoprotein cholesterol (mmol/L)** | 1.66 ± 0.51             | 1.65 ± 0.48         | 0.9552    |
| **Low-density lipoprotein cholesterol (mmol/L)** | 2.88 ± 0.72             | 3.38 ± 1.51         | 0.2972    |
| **Triglyceride (mmol/L)**      | 1.18 ± 1.00             | 1.49 ± 1.24         | 0.3828    |
| **High density lipoprotein (mg/L)** | 180 ± 2.20              | 243 ± 2.27          | 0.3828    |
| **Thyroid-stimulating hormone (mIU/L)** | 2.09 ± 2.35             | 1.85 ± 1.87         | 0.7369    |
| **Body mass index (kg/m²)**    | 249.7 ± 4.95            | 245.1 ± 4.84        | 0.7924    |
| **Sex (female/male)**          | 66/59 (52.8%/47.2%)     | 16/12 (57.1%/42.9%) | 0.9907    |
| **Latent autoimmune diabetes of adults** | 29 (23.2%)              | 4 (14.3%)           | 0.7237    |
| **Hypertension**               | 40 (32%)                | 12 (42.9%)          | 0.6380    |
| **Autoimmune disease**         | 15 (12%)                | 8 (28.6%)           | 0.1231    |
| Vitiligo                       | 4 (3.2%)                | 2 (7.1%)            | 0.6380    |
| Alopecia areata                | 5 (4%)                  | 0 (0%)              | 0.8342    |
| Pernicious anemia              | 2 (1.6%)                | 4 (14.3%)           | 0.1009    |
| Celiac disease                 | 2 (1.6%)                | 1 (3.6%)            | 0.7237    |
| Addison’s disease              | 1 (0.8%)                | 0 (0%)              | 1.0000    |
| Sjögren’s syndrome             | 0 (0%)                  | 1 (3.6%)            | 0.4697    |
| Psoriasis vulgaris             | 1 (0.8%)                | 0 (0%)              | 1.0000    |
| Thyroid disease                | 39 (31.2%)              | 10 (35.7%)          | 0.8342    |
| Hashimoto’s thyroiditis        | 31 (24.8%)              | 5 (17.9%)           | 0.8342    |
| Hyperthyroidism                | 7 (5.6%)                | 3 (10.7%)           | 0.7237    |
| Hypothyroidism                 | 1 (0.8%)                | 0 (0%)              | 1.0000    |
| Thyroid nodules                | 0 (0%)                  | 2 (7.1%)            | 0.1231    |

Unit of non-laboratory data is the number of observations. CgA, chromogranin A; HbA1C, glycated hemoglobin. $P$-values of statistically different results between the two cohorts are indicated with bold text.
these groups (Table 3). The serum gastrin level was also investigated in patients with gastroscopy, and gastrin levels in the High CgA group were significantly higher (48.12 ± 50.97 pg/mL vs 351.05 ± 252.66 pg/mL, P < 0.0001). A significant positive correlation was found between CgA and gastrin (Pearson’s R = +0.59, P = 0.0009), and the increase in gastrin moderately explained the increase in CgA (adjusted R² = 0.3286, P = 0.0004).

ECL hyperplasia positivity (ECL⁺) occurs significantly more often in female patients (85% of 20 women vs 42.9% of 14 men, P = 0.0383) in accordance with previous findings. ECL⁺ was present in 16 of the 19 High CgA patients (odds ratio 5.74, 95% CI 1.0001–44.1643) compared with seven of the 15 Normal CgA patients (P = 0.0087). The specificity and sensitivity of CgA were analyzed to predict ECL⁺; CgA had 90.9% specificity and 45.5% sensitivity, with an optimal CgA cut-off point of 183.35 ng/mL (Figure 1a). The distribution of hyperplasia types was significantly different (P = 0.0087, P-values were the same after FDR correction of multiple comparisons) between the two groups. Diffuse ECL hyperplasia occurred in both the Normal CgA group and the High CgA group, but more advanced forms of hyperplasia were found only in the patients of the High CgA group (Table 3).

AIG was also more frequent in women (P = 0.0023), as described before. Histologically-confirmed AIG was significantly more frequent (P = 0.0087) in the High CgA group (9 AIG cases vs 0 cases, odds ratio ∞ due to division by zero, CI 95% 2.23–∞). To detect AIG, CgA has a 48% specificity and 100% sensitivity, with an optimal CgA cut-off point of 100.50 ng/mL (Figure 1a). Red blood cell counts (P = 0.0336), hemoglobin (P = 0.0167) and hematocrit (P = 0.0167) levels in the High CgA group were significantly lower (Table 1), in accordance with the described consequences of AIG.

Progression of ECL hyperplasia in patients with continuously high serum CgA levels

The examination of archive biopsy samples could be carried out in 11 of the 19 patients in the High CgA group. Archived biopsy samples were collected 3.94 ± 1.96 years before the gastroscopy. A significantly (P = 0.0192) higher number of more advanced hyperplasia stages were observed at the recent gastroscopical examination compared with the archive samples (Table 4). Just four of the patients had no changes at all, and a progression was observed in seven patients.

The serum CgA levels of patients with and without progression were compared with a one-sided paired t-test. Serum CgA levels were significantly higher (P = 0.0316) at recent gastroscopy in patients with ECL hyperplasia progression (Figure 1b), whereas they did not differ in patients without histological progressions (P = 0.3752).

DISCUSSION

Newly-diagnosed type 1 diabetes patients have shown elevated WE-14-induced CD4⁺ CgA10–19⁺ and CgA43–52-fragment-related, CD8⁺ β-cell-specific diabetogenic T-cell antigenicity, suggesting that these CgA cleavage products contribute to the pathogenesis of type 1 diabetes. However, there is little information about the relationship between CgA and the
Figure 1 | (a) Receiver operating characteristic (ROC) curve of chromogranin A to detect enterochromaffin-like neuroendocrine hyperplasia and autoimmune gastritis ($n = 34$). The two curves do not differ significantly ($P = 0.5615$). (b) Changes in serum chromogranin A levels of the patients who had progression in their neuroendocrine enterochromaffin-like (ECL) hyperplasia types between the two gastroscopies ($P = 0.0316$). AUC, area under the curve.
Chromogranin A-specific immunohistochemistry

Serum chromogranin A (ng/mL)
of observation has been inserted.

Results between the two cohorts are indicated with bold text. [Correction added on 18 May 2020, after first online publication: A missing number from the group had no serum chromogranin A (CgA) measurement around the time of archive gastroscopy results.

The present study showed that approximately 20% of the type 1 diabetes patients had CgA levels above the upper limit of the normal range. There are no pancreatic β-cells in the patients long after the first onset; therefore, our observation is not connected to the CgA product-sensitive, β cell-specific T cells in all probability.

ECL hyperplasia and AIG occurred more frequently in our type 1 diabetes patients with high CgA levels, similar to the finding that ECL hyperplasia and AIG more often occur in type 1 diabetes patients with PCA positivity. Approximately 50% of our patients with high CgA levels and ECL+ also had AIG, in accordance with the known connection between ECL+ and AIG. Significantly lower hemoglobin and hematocrit values, and red blood cell counts, were detected in the High CgA group, which can be explained by the higher presence of AIG within the group, accompanied by various forms of anemia. In addition, ECL hyperplasia and AIG occur more often in women, which we also observed.

The prospective branch of the current study showed a slow, but steady, rise in CgA level over time, and the patients with high CgA levels had more progressed ECL hyperplasia stages, indicating the progression of ECL hyperplasia. Although the low number of archived gastroscopy samples did not enable us to carry out a full prospective investigation on tissue samples, the comparison of biopsy samples from recent gastroscopy to archived biopsy samples showed that the ECL hyperplasia stages in type 1 diabetes patients of the High CgA group progressed, which was also accompanied by a rise in serum CgA levels. CgA levels did not change significantly in the patients of the High CgA group who had a lack of ECL hyperplasia progression. The observed connection between the serum and histological results strongly suggest that the histological changes in the gastric mucosa cause the elevation of CgA levels in type 1 diabetes patients. This is also supported by the higher serum gastrin levels in the High CgA group, which indicates the gastric origin of CgA, although CgA is an independent risk factor from PCA and gastrin for ECL hyperplasia in type 1 diabetes patients. Unfortunately, the present findings do not allow us to determine whether ECL hyperplasia or AIG develops first, and what is the exact pathomechanism. As AIG was only observed together with linear or micronodular ECL hyperplasia stages and high CgA levels, and ECL hyperplasia was also present in patients within normal CgA levels and without AIG, it might be considered as a sign that ECL hyperplasia is the one that develops first. Nevertheless, ECL cell hyperplasia and AIG can both be a basis of developing gastric NETs, which has 100-fold increased prevalence in type 1 diabetes patients.

The significance of CgA levels in the diagnosis of type 1 diabetes was shown by one of our cases; high CgA levels helped to detect a silent gastric NET on the basis of ECL hyperplasia in a female type 1 diabetes patient. After tumor removal, her serum CgA level returned to the normal range.

Serum CgA is used as a marker of various neuroendocrine tumors and it has been proven to be a good marker to track the progression of both ECL hyperplasia and gastric NETs. CgA levels far above the normal range clearly indicated the presence of ECL hyperplasia in patients with type 1 diabetes according to the data of receiver operating characteristic curves, but the optimal cut-off point was higher than the upper limit of the normal range, resulting in a high number of unidentified ECL hyperplasia with CgA values between these two points. The value of the optimal CgA cut-off point for AIG was practically the same as the upper limit of the normal range, and there were no unidentified AIG cases based on these CgA levels. Last but not least, CgA levels far above the normal range characterized well the progression of ECL hyperplasia.

In all probability, elevated serum CgA levels in patients far from first onset of type 1 diabetes were caused by gastric ECL hyperplasia and AIG. AIG is a known comorbidity of type 1 diabetes, appearing during the progression of type 1 diabetes; therefore, it is not surprising that the CgA level showed a weak, but significant correlation with HbA1C, and was also associated with the glycemic control of patients. During the

Table 4 | Distributional changes of neuroendocrine enterochromaffin-like hyperplasia types and serum chromogranin A levels at the two gastroscopy examinations

| High CgA (n = 11) | Archived gastroscopy samples | Recent gastroscopy | P-value |
|------------------|-------------------------------|--------------------|--------|
| Chromogranin A-specific immunohistochemistry | | | |
| Negative | 8 (72.7%) | 2 (18.2%) | 0.0192 |
| Diffuse ECL hyperplasia | 0 (0%) | 5 (45.4%) |
| Linear ECL hyperplasia | 2 (18.2%) | 2 (18.2%) |
| Micronodular ECL hyperplasia | 1 (9.1%) | 2 (18.2%) |
| Serum chromogranin A (ng/mL) | | | |
| Patients with histological change (n = 6) | 411.75 ± 469.88 (161.00–327.05) | 713.53 ± 766.97 (233.05–767.15) | 0.0316 |
| Patients without histological change (n = 4) | 197.53 ± 131.31 (120.83–219.99) | 164.68 ± 67.82 (128.43–178.85) | 0.3752 |

Unit of enterochromaffin-like (ECL) hyperplasia data is the number of observations. Mean ± standard deviation (interquartile range). *One patient from the group had no serum chromogranin A (CgA) measurement around the time of archive gastroscopy results. P-values of statistically different results between the two cohorts are indicated with bold text. [Correction added on 18 May 2020, after first online publication: A missing number of observation has been inserted.]
present study, we made a preliminary, but clinically interesting, observation that glycemic control could not have been efficiently normalized in most of our patients with high CgA, despite their good compliance. We do not know the potential cause of the bad glycemic control in patients with high CgA levels and without compliance issues, but we cannot rule out that elevated CgA or one of its cleavage products (for example, pancreastatin) due to ECL hyperplasia-AIG exert an influence on glycemic control.

There is no consensus regarding the usefulness of CgA as a marker in diabetes at the present time. It has been previously suggested that further testing is necessary to evaluate the usefulness of CgA in diabetes, whereas others have suggested that testing the combination of serum CgA, gastrin and PCA might be equivalent to histological examinations to detect premalignant lesions of gastric NETs, and would be recommended. G cells producing gastrin, ECL cells producing CgA and parietal cells covered by the antigens of PCA have a complex, functional relationship in gastric glands. PCA is applied to indicate AIG. However, PCA cannot be used to follow up the progression of the AIG due to the loss of gastric parietal cells, nor can it be used to predict and follow up premalignant histological changes and gastric NETs, contrary to CgA. The gastrin serum level gives only indirect information on ECL cell progression, because it is produced by gastric G cells, whereas CgA is a direct product of gastric ECL cells. Based on the observations of the current study, the routine measurement of CgA in patients with type 1 diabetes would indicate ECL and AIG reasonably well. Progressively increasing CgA levels would be a good indicator of the need for histological examination by gastroscopy. It would be possible to follow up the progression of ECL hyperplasia toward gastric neuroendocrine tumors by using CgA measurements in type 1 diabetes patients who already have CgA levels above the normal range and ECL hyperplasia-AIG confirmed by biopsy. Therefore, CgA should be considered as an auxiliary marker for the early detection and follow up of ECL hyperplasia and AIG in diabetes care.

ACKNOWLEDGMENTS
The authors thank all members of staff who worked on laboratory measurements at Semmelweis University. We are grateful to Mark Eyre for English proofreading. ZH was supported by the “Wörwag Research Prize for PhD students”, announced by Wörwag Pharma Kft. MD was supported by Janos Bolyai Research Scholarship from the Hungarian Academy of Sciences, and the UNKP-19-4 New National Excellence Program of the Ministry for Innovation and Technology. Research was supported by a grant from the National Research, Development and Innovation Office (K-116128), and by a Research Grant from the Hungarian Diabetes Association.

DISCLOSURE
The authors declare no conflict of interest.

REFERENCES
1. Gluckman CR, Metz DC. Gastric neuroendocrine tumors (carcinoids). Curr Gastroenterol Rep 2019; 21: 13–20.
2. Tseng CH. Diabetes conveys a higher risk of gastric cancer mortality despite an age-standardised decreasing trend in the general population in Taiwan. Gut 2011; 60: 774–779.
3. Shu X, Ji J, Li X, et al. Cancer risk among patients hospitalized for type 1 diabetes mellitus: a population-based cohort study in Sweden. Diabet Med 2010; 27: 791–797.
4. Harding JL, Shaw JE, Peeters A, et al. Cancer risk among people with type 1 and type 2 diabetes: disentangling true associations, detection bias, and reverse causation. Diabetes Care 2015; 38: 264–270.
5. Solcia E, Bordi C, Creutzfeldt W, et al. Histopathological classification of nonantral gastric endocrine growths in man. Digestion 1988; 41: 185–200.
6. De Block CE, Colpin G, Thielemans K, et al. Neuroendocrine tumor markers and enterochromaffin-like cell hyper/dysplasia in type 1 diabetes. Diabetes Care 2004; 27: 1387–1393.
7. De Block CE, De Leeuw IH, Van Gaal LF. Autoimmune gastritis in type 1 diabetes: a clinically oriented review. J Clin Endocrinol Metab 2008; 93: 363–371.
8. Bizzaro N, Antico A, Villalta D. Autoimmunity and gastric cancer. Int J Mol Sci 2018; 19: 377–390.
9. Krzewska A, Ben-Skowronek I. Effect of associated autoimmune diseases on type 1 diabetes mellitus incidence and metabolic control in children and adolescents. Biomed Res Int 2016; 2016; Article ID 6219730.
10. Hanssen MP, Matheis N, Kahaly GJ. Type 1 diabetes and polyglandular autoimmune syndrome: A review. World J Diabetes 2015; 6: 67–79.
11. Kalkan C, Karakaya F, Soykan I. Factors associated with elevated serum chromogranin A levels in patients with autoimmune gastritis. Turk J Gastroenterol 2016; 27: 515–520.
12. Plockinger U. Diagnosis and treatment of gastric neuroendocrine tumours. Wien Klin Wochen 2007; 119: 570–572.
13. Herold Z, Doleschall M, Kovesdi A, et al. Chromogranin A and its role in the pathogenesis of diabetes mellitus. Endokrynol Pol 2018; 69: 598–610.
14. Konecki DS, Benedum UM, Gerdes HH, et al. The primary structure of human chromogranin A and pancreastatin. J Biol Chem 1987; 262: 17026–17030.
15. Yoo SH, Lewis MS. Effects of pH and Ca2+ on monomer-dimer and monomer-tetramer equilibria of chromogranin A. J Biol Chem 1992; 267: 11236–11241.
16. Gorr SU, Dean WL, Radley TL, et al. Calcium-binding and aggregation properties of parathyroid secretory protein-I (chromogranin A). Bone Miner 1988; 4: 17–25.
17. Dirkx R Jr, Solimena M. Cholesterol-enriched membrane rafts and insulin secretion. J Diabetes Invest 2012; 3: 339–346.
18. Eskeland NL, Zhou A, Dinh TQ, et al. Chromogranin A processing and secretion: Specific role of endogenous and exogenous prohormone convertases in the regulated secretory pathway. J Clin Invest 1996; 98: 148–156.

19. Helle KB, Metz-Boutigue MH, Cerra MC, et al. Chromogranins: from discovery to current use. Pflugers Arch 2018; 470: 143–154.

20. Vinik AI, Silva MP, Woltering EA, et al. Biochemical testing for neuroendocrine tumors. Pancreas 2009; 38: 876–889.

21. Glinicki P, Jeske W. Chromogranin A (CgA) - the influence of various factors in vivo and in vitro, and existing disorders on its concentration in blood. Endokrynol Pol 2010; 61: 384–387.

22. Pregun I, Herszenyi L, Juhasz M, et al. Effect of proton-pump inhibitor therapy on serum chromogranin a level. Digestion 2011; 84: 22–28.

23. Broedbaek K, Hilsted L. Chromogranin A as biomarker in diabetes. Biomark Med 2016; 10: 1181–1189.

24. Troger J, Theurl M, Kirchmair R, et al. Granin-derived peptides. Prog Neurobiol 2017; 154: 37–61.

25. Sanchez-Margalet V, Lobon JA, Gonzalez A, et al. Increased plasma pancreastatin-like levels in gestational diabetes: correlation with catecholamine levels. Diabet Care 1998; 21: 1951–1954.

26. Gottlieb PA, Delong T, Baker RL, et al. Chromogranin A is a T cell antigen in human type 1 diabetes. J Autoimmun 2014; 50: 38–41.

27. Li Y, Zhou L, Li Y, et al. Identification of autoreactive CD8+ T cell responses targeting chromogranin A in humanized NOD mice and type 1 diabetes patients. Clin Immunol 2015; 159: 63–71.

28. Stadinski BD, Delong T, Reisdorph N, et al. Chromogranin A is an autoantigen in type 1 diabetes. Nat Immunol 2010; 11: 225–231.

29. Decochez K, Tits J, Coolens JL, et al. High frequency of persisting or increasing islet-specific autoantibody levels after diagnosis of type 1 diabetes presenting before 40 years of age. The Belgian Diabetes Registry. Diabet Care 2000; 23: 838–844.

30. American Diabetes Association. 6. Glycemic targets: Standards of medical care in diabetes-2019. Diabetes Care 2019; 42: 561–570.

31. Schwandt A, Denkinger M, Fasching P, et al. Comparison of MDRD, CKD-EPI, and Cockcroft-Gault equation in relation to measured glomerular filtration rate among a large cohort with diabetes. J Diabet Complicat 2017; 31: 1376–1383.

32. Nolting S, Kuttner A, Lauseker M, et al. Chromogranin a as serum marker for gastroenteropancreatic neuroendocrine tumors: a single center experience and literature review. Cancers 2012; 4: 141–155.

33. Stridsberg M, Eriksson B, Oberg K, et al. A comparison between three commercial kits for chromogranin A measurements. J Endocrinol 2003; 177: 337–341.

34. Fischer AH, Jacobson KA, Rose J, et al. Hematoxylin and eosin staining of tissue and cell sections. CSH Protocols 2008; 2008: pdb.prot4986–pdb.prot4986.

35. Gray SF, Wyatt JJ, Rathbone BJ. Simplified techniques for identifying Campylobacter pyloridis. J Clin Pathol 1986; 39: 1279.

36. Stolte M, Meining A. The updated Sydney system: classification and grading of gastritis as the basis of diagnosis and treatment. Can J Gastroenterol 2001; 15: 591–598.

37. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing, 2019.

38. Johnson DH. Statistical sirens: the allure of nonparametrics. Ecology 1995; 76: 1998–2000.

39. Rietveld T, van Hout R. The paired t test and beyond: Recommendations for testing the central tendencies of two paired samples in research on speech, language and hearing pathology. J Commun Disord 2017; 69: 44–57.

40. Pinheiro J, Bates D, DebRoy S, et al. (nlme): Linear and nonlinear mixed effects models. 2019.

41. Miceli E, Lenti MV, Padula D, et al. Common features of patients with autoimmune atrophic gastritis. Clin Gastroenterol Hepatol 2012; 10: 812–814.

42. Delong T, Baker RL, He J, et al. Diabetogenic T-cell clones recognize an altered peptide of chromogranin A. Diabetes 2012; 61: 3239–3246.

43. Baker RL, Bradley B, Wiles TA, et al. Cutting edge: Nonobese diabetic mice deficient in chromogranin A are protected from autoimmune diabetes. J Immunol 2016; 196: 39–43.

44. Katsarou A, Gudbjornsdottir S, Rawshani A, et al. Type 1 diabetes mellitus. Nat Rev Dis Primers 2017; 3: 17016.

45. De Block CE, De Leeuw IH, Bogers JJ, et al. Autoimmune gastropathy in type 1 diabetic patients with parietal cell antibodies: histological and clinical findings. Diabetes Care 2003; 26: 82–88.

46. Peracchi M, Gebbia C, Basilisco G, et al. Plasma chromogranin A in patients with autoimmune chronic atrophic gastritis, enterochromaffin-like cell lesions and gastric carcinoids. Eur J Endocrinol 2005; 152: 443–448.

47. Somogyi A, Ruzicska E, Varga T, et al. Development of silent gastric carcinoma in a type 1 diabetic patient with primer hypothyreosis. Orv Hetil 2007; 148: 1667–1671 (Hungarian).

48. Zhao CM, Chen D. The ECL cell: relay station for gastric integrity. Curr Med Chem 2012; 19: 98–108.

49. Malfertheiner P, Kandulska A, Venerito M. Proton-pump inhibitors: understanding the complications and risks. Nat Rev Gastroenterol Hepatol 2017; 14: 697–710.

50. Antico A, Tampoia M, Villalta D, et al. Clinical usefulness of the serological gastric biopsy for the diagnosis of chronic autoimmune gastritis. Clin Dev Immunol 2012; 2012: 520970.